𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝘁𝗼𝗹𝗱 𝗺𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗽𝗵𝗮𝗿𝗺𝗮 𝘁𝗲𝗮𝗺𝘀 𝗰𝗮𝗻𝗻𝗼𝘁 𝗱𝗼 𝗔𝗜 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗥𝘅 𝗱𝗮𝘁𝗮. 𝗧𝗵𝗲𝘆 𝘄𝗲𝗿𝗲 𝘄𝗿𝗼𝗻𝗴.

For years, that was the excuse. No individual prescription data in Germany, France, or most of Europe meant we could not do what US teams do. So we stuck with rep estimates, annual A/B/C grids, and gut feeling. Updated once a year. Called it a targeting strategy.

Here is what actually happened while we were waiting: a new generation of AI vendors built solutions that do not need Rx data at all.

𝗪𝗵𝗮𝘁 𝗶𝘀 𝗻𝗼𝘄 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝗶𝗻 𝗘𝘂𝗿𝗼𝗽𝗲 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻 𝗿𝗲𝗰𝗼𝗿𝗱:

𝟭. AI platforms like PeakData scan 5M+ physician profiles across 15+ countries, mapping publication activity, congress presentations, clinical trial involvement, and peer influence networks. That is richer targeting intelligence than a volume decile ever was.

𝟮. Propensity engines like ODAIA MAPTUAL use ML to dynamically re-rank your HCP targets based on engagement signals. In one case study: 18,000 HCPs analyzed, 7,000 re-flagged as high-value that the old grid had missed. 8x ROI. No Rx data required.

𝟯. Double deciling (potential x channel responsiveness) generates 30% more engagement than single-dimension targeting (BCG, 2025). The second axis runs entirely on behavioral data you are already collecting.

𝟰. Field NBA engines now integrate natively into Veeva CRM. Reps who follow NBA suggestions see 14% higher sales within 9 months (Aktana, 2025). Three viable vendor paths exist for European teams today.

𝟱. Cross-functional orchestration coordinates sales, marketing, and medical through a single engine. 5 to 15% revenue uplift for companies that get here (BCG, 2025). ODAIA, ZS ZAIDYN, and Salesforce Agentforce are all live.

The behavioral data your team generates daily (CRM logs, email opens, webinar attendance, event participation) is often more predictive of future prescribing behavior than historical volume deciles (Marketing Advantage, 2024). The absence of Rx data was never the real problem. The real problem was treating it as an excuse to do nothing.

My daughters once spent an entire weekend sorting LEGO by color. Then they realized sorting by set would have been more useful. Same energy as clinging to your annual decile grid when you could be using engagement intelligence that updates weekly.

If your European team is still waiting for Rx data before modernizing targeting, you are solving for a constraint that no longer exists. At ImpactWorks we help pharma and life sciences teams move from static segments to dynamic, AI-driven targeting, one maturity level at a time.

#HCPTargeting #PharmaSales #NextBestAction #DynamicSegmentation #AIinPharma #LifeSciences